These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32790844)

  • 1. Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study.
    Yeshurun M; Rozovski U; Pasvolsky O; Wolach O; Ram R; Amit O; Zuckerman T; Pek A; Rubinstein M; Sela-Navon M; Raanani P; Shargian-Alon L
    Blood Adv; 2020 Aug; 4(16):3822-3828. PubMed ID: 32790844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT.
    Hudspeth MP; Heath TS; Chiuzan C; Garrett-Mayer E; Nista E; Burton L; Ragucci D
    Bone Marrow Transplant; 2013 Jan; 48(1):46-9. PubMed ID: 22609886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.
    Freyer CW; Gier S; Moyer ME; Berryman N; Carulli A; Ganetsky A; Timlin C; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy S; Perl AE; Smith J; Luger SM; Stadtmauer EA; Porter DL
    Transplant Cell Ther; 2021 May; 27(5):431.e1-431.e8. PubMed ID: 33965188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention.
    Hamilton BK; Rybicki LA; Li H; Lucas T; Corrigan D; Kalaycio M; Sobecks R; Hanna R; Rotz SJ; Dean RM; Gerds AT; Jagadeesh D; Brunstein C; Sauter CS; Copelan EA; Majhail NS
    Blood Adv; 2023 Aug; 7(16):4505-4513. PubMed ID: 37352262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
    Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
    Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation.
    AlJohani NI
    Hematology; 2021 Dec; 26(1):620-627. PubMed ID: 34411497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
    Yeshurun M; Shpilberg O; Herscovici C; Shargian L; Dreyer J; Peck A; Israeli M; Levy-Assaraf M; Gruenewald T; Mechoulam R; Raanani P; Ram R
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1770-5. PubMed ID: 26033282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation.
    Torres A; Martinez F; Gomez P; Herrera C; Rojas R; Gomez-Villagran JL; Garcia-Castellano JM; Velasco F; Andres P; Fornes G
    Blut; 1989 Feb; 58(2):63-8. PubMed ID: 2645954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis.
    Al-Jamaei AAH; Epstein JB; de Visscher JGAM; Spielberger RT; Nakamura R; Raber-Durlacher JE
    Support Care Cancer; 2024 Jul; 32(8):519. PubMed ID: 39017899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
    Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
    Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on graft-versus-host disease in the allogeneic peripheral blood stem cell transplantation for the treatment of leukemia].
    Zhang WP; Wang JM; Ju XP; Song XM; Tong SP; Li HM
    Zhonghua Xue Ye Xue Za Zhi; 2003 Mar; 24(3):129-33. PubMed ID: 12697123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial.
    Chao NJ; Snyder DS; Jain M; Wong RM; Niland JC; Negrin RS; Long GD; Hu WW; Stockerl-Goldstein KE; Johnston LJ; Amylon MD; Tierney DK; O'Donnell MR; Nademanee AP; Parker P; Stein A; Molina A; Fung H; Kashyap A; Kohler S; Spielberger R; Krishnan A; Rodriguez R; Forman SJ; Bluzme KG
    Biol Blood Marrow Transplant; 2000; 6(3):254-61. PubMed ID: 10871150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
    Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
    Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation.
    Robien K; Schubert MM; Yasui Y; Martin P; Storb R; Potter JD; Ulrich CM
    Bone Marrow Transplant; 2006 Apr; 37(7):687-92. PubMed ID: 16501595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.
    Snyder DS; Palmer J; Gaal K; Stein AS; Pullarkat V; Sahebi F; Vora N; Nakamura R; Forman SJ
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):281-6. PubMed ID: 19786111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.